Posterior Segment Drug Delivery Devices: Current and Novel Therapies in Development

Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
Pooja BansalPradeep Venkatesh

Abstract

Ocular drug delivery by conventional routes of administration does not maintain therapeutic drug concentrations in the target tissues for a long duration because of various anatomical and physiological barriers. Treatment of diseases of the posterior segment of the eye requires novel drug delivery systems that can overcome these barriers for efficacious delivery, provide controlled release for the treatment of chronic diseases, and increase patient's and doctor's convenience to reduce the dosing frequency and associated side effects. Thereby, an increasing number of sustained-release drug delivery devices using different mechanisms have been developed. This article discusses various current and future sustained-release drug delivery systems for the posterior segment disorders.

References

Jan 1, 1992·Journal of Ocular Pharmacology·P AshtonG E Sanborn
Apr 1, 1990·Clinical Pharmacokinetics·R D Schoenwald
Nov 1, 1996·Survey of Ophthalmology·J Burke, M Schwartz
Apr 16, 1998·Progress in Retinal and Eye Research·C L BourlaisR Leverge
Dec 31, 2002·Investigative Ophthalmology & Visual Science·Karen G CarrasquilloAnthony P Adamis
Jun 14, 2003·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Thomas M ParkinsonMohan Mundasad
Jul 11, 2003·Survey of Ophthalmology·Larry WheelerRonald Lai
Oct 28, 2003·Investigative Ophthalmology & Visual Science·Yoshitsugu SaishinPeter A Campochiaro
Apr 27, 2004·Experimental Eye Research·M HalhalF Behar-Cohen
Mar 8, 2005·Survey of Ophthalmology·Shehab EbrahimPaul J Lee
Apr 29, 2005·Current Drug Targets·Rubiana Mara MainardesMaria Palmira Daflon Gremiao
Sep 23, 2006·American Journal of Ophthalmology·Timothy W OlsenJ Douglas Cameron
Nov 14, 2006·Advanced Drug Delivery Reviews·Arto Urtti
Feb 16, 2008·Drug Discovery Today·Eva M Del Amo, Arto Urtti
Sep 10, 2008·Archives of Ophthalmology·David G CallananTimothy L Comstock
Feb 3, 2009·Pharmaceutical Research·Saffar MansoorM Cristina Kenney
Sep 16, 2009·Archives of Ophthalmology·Steven YehChristina J Flaxel
Feb 9, 2010·The British Journal of Ophthalmology·Rishi P SinghAlan Riga
Mar 23, 2010·Expert Review of Ophthalmology·Shalin S ShahJames M Hill
Sep 22, 2010·Pharmaceutical Research·Samirkumar R PatelMark R Prausnitz
Dec 21, 2010·Drug Discovery Today·Thilini Rasika ThrimawithanaRaid Ghassan Alany
Mar 30, 2011·Proceedings of the National Academy of Sciences of the United States of America·Kang ZhangGeorge A Williams
Mar 31, 2011·Investigative Ophthalmology & Visual Science·Timothy W OlsenJ Douglas Cameron
Apr 14, 2011·Retina·David S BoyerUNKNOWN Ozurdex CHAMPLAIN Study Group
Oct 1, 2011·Journal of Ophthalmic Inflammation and Infection·Reema BansalAmod Gupta
Feb 23, 2012·Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift für Augenheilkunde·Manfred TetzAlbert J Augustin
Dec 22, 2012·Ophthalmic Research·Dicle Hazirolan, Uwe Pleyer
Jan 18, 2013·Ocular Immunology and Inflammation·Soraya RofaghaJay M Stewart
Feb 20, 2013·Ophthalmology·Douglas A JabsUNKNOWN Studies of the Ocular Complications of AIDS Research Group
Feb 27, 2013·International Journal of Nanomedicine·Miki HondaNobuyuki Ebihara
Apr 18, 2013·Ocular Immunology and Inflammation·Levent AkdumanLyndell L Lim
Aug 15, 2013·Ocular Immunology and Inflammation·Adit GuptaVishali Gupta
May 13, 2014·Journal français d'ophtalmologie·S GuigouF Meyer

❮ Previous
Next ❯

Citations

Dec 7, 2016·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·L David Waterbury
Apr 21, 2017·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Rohit BishtIlva D Rupenthal
Dec 15, 2016·Expert Opinion on Drug Delivery·Vibhuti AgrahariAshim K Mitra
Apr 4, 2017·Journal of Biomedical Materials Research. Part B, Applied Biomaterials·Taro KondoHirokazu Kaji
Jul 25, 2017·ACS Applied Materials & Interfaces·Raghu GanugulaMajeti N V Ravi Kumar
Dec 12, 2017·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·L David Waterbury
Apr 27, 2019·Macromolecular Bioscience·Deqing LinXingyi Li
Jul 2, 2019·Biomedical Microdevices·Yuto SatoHirokazu Kaji
Mar 24, 2017·Nature Communications·Joy G GhoshMichael Roguska
Oct 25, 2017·Current Ophthalmology Reports·João Rafael de Oliveira DiasRaquel Goldhardt
Apr 17, 2020·Pharmaceutics·Rosario Pignatello, Pietro Matricardi
Sep 3, 2020·International Journal of Pharmaceutics·Isabela Fernandes de OliveiraNádia Bou-Chacra
Jun 9, 2019·Drug Discovery Today·Fernando J CabreraCrystal S Shin
Sep 28, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Kritika Nayak, Manju Misra
May 16, 2021·International Journal of Pharmaceutics·Blanca Lorenzo-VeigaHakon Hrafn Sigurdsson

❮ Previous
Next ❯

Methods Mentioned

BETA
transfection

Software Mentioned

Visulex
EyeGate
OcuPhor
Vitrasert

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Ophthalmic & Vision Research
Nahid HaghjouMohammad Jafar Abdekhodaie
Current Opinion in Molecular Therapeutics
Jennifer L DavisMichael R Robinson
Recent Patents on Drug Delivery & Formulation
Barbara R Conway
© 2021 Meta ULC. All rights reserved